Anticardiolipin Antibodies Are Elevated in HIV-1 Infected Haemophiliacs but Do Not Predict for Disease Progression

Summary

Levels of anticardiolipin antibodies (ACA) were measured in 55 patients with haemophilia A in serum samples obtained in 1983 and in 1987. Twenty-one patients were negative for anti HIV-1 antibodies in 1983 and remained negative in 1987; 34 patients had anti HIV-1 antibodies in 1983; 17 of these latter patients remained asymptomatic, whereas 17 patients developed ARC or AIDS during the 4 years follow-up. Thirteen anti HIV-1 negative patients had elevated ACA levels in 1983; subsequently, a significant decrease was observed in all these subjects (p <0.001). All anti HIV-1 positive patients had elevated ACA levels in 1983; normal values were found in 9 patients in 1987. Yet, these changes were not significant (p >0.05). ACA levels were significantly higher in HIV-1 infected patients than in those without anti HIV-1 antibodies (p <0.05). There was no difference of ACA levels between the two anti HIV-1 positive patient groups, be it in 1983 or be it in 1987 (p >0.05). There was no correlation of ACA levels with serum IgG concentrations, CD4⁺ lymphocytes, or the consumption of factor VIII concentrates.

Key words

Anticardiolipin antibodies - Haemophilia A - HIV-1 infection

• References

• 1 Smolarsky M. A simple radioimmunoassay to determine binding of antibodies to lipid antigens. J Immunol Methods 1980; 38: 85-93
• 2 Harris EN, Asherson RR, Gharavi AE. Thrombocytopenia in SLE and related disorders: association with anticardiolipin antibodies. Br J Haematol 1985; 59: 227-230
• 3 Ratnoff OB, Menitove JE, Aster RH, Lederman MM. Coincident classic hemophilia and “idiopathic” thrombocytopenic purpura in patients and treatment with concentrates of antihemophilic factor (factor VIII). N Engl J Med 1983; 308: 439-442
• 4 Panzer S, Zeitelhuber V, Hack V, Brackmann HH, Niessner H, Mueller-Eckhardt C. Immune thrombocytopenia in severe hemophilia treated with high-dose intravenous immunoglobulin. Transfusion 1986; 26: 69-72
• 5 Walsh CM, Nardi MA, Karpatkin S. On the mechanism of thrombocytopenic purpura in sexually active homosexual men. N Engl J Med 1984; 311: 635-639
• 6 Cohen AJ, Philips TM, Kessler CM. Circulating coagulation inhibitors in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 104: 175-180
• 7 Gold JE, Haubenstock A, Zalusky R. Lupus anticoagulant and AIDS. N Engl J Med 1986; 314: 1252-1253 (Letter)
• 8 Manoussakis MN, Gharavi AE, Drosos AA, Kitridou RC, Moutsopoutos HM. Anticardiolipin antibodies in unselected autoimmune rheumatic disease patients. Clin Immunol Immunopathol 1987; 44: 297-307
• 9 Canoso RT, Zon LI, Groopman JE. Anticardiolipin antibodies associated with HTLV-III infection. Br J Haematol 1987; 65: 495-498
• 10 Centers for disease control, U.S. Department of Health and Human Services, Atlanta, Georgia. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. Ann Intern Med 1986; 105: 234-237
• 11 Harris EN, Haravi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizon S, Hughes GR V. Anticardiolipin antibodies: detection with radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-1214
• 12 Lechner K, Niessner H, Bettelheim P, Deutsch E, Fasching I, Fuhrmann M, Hinterberger W, Korninger C, Neumann E, Liszka K, Knapp W, Mayr W R, Stingl G, Zeitlhuber U. T-cell alternations in hemophiliacs treated with commercial clotting factor concentrates. Thromb Haemostas 1983; 50: 552-556
• 13 Brien W, Inwood M, Denome G. Antiphospholipid antibodies in haemophiliacs. Br J Haematol 1988; 67: 270 (Letter)
• 14 Panzer S, Pabinger I, Dudczak R, Wurz E, Lechner K. Protein S and anticardiolipin antibodies in patients with lupus anticoagulant with or without thrombosis. Thromb Haemostas 1987; 58: 392 (Abstr)
• 15 Intrator L, Ohsenhendler E, Desforges L, Bierling P. Anticardiolipin antibodies in HIV infected patients with or without immune throm-bocytopenic purpura. Br J Haematol 1988; 67: 269 (Letter)
• 16 Eibl MM, Ahmad R, Wolf HM, Linnau Y, Gotz E, Mannhalter JW. A component factor VIII preparations which can be separated from factor VIII activity down modulates monocyte functions. Blood 1987; 69: 1153-1160
• 17 Mannhalter JW, Ahmad R, Leibl H, Gottlicher J, Wolf HM, Eibl MM. Comparable modulation of human monocyte functions by com-mercial FVIII concentrates of varying purity. Blood 1988; 71: 1662-1668
• 18 Barrowcliffe TW, Kemball-Cook G, Gray E. Factor VIII inhibitor by passing activity: a suggested mechanism of actions. Thromb Res 1981; 21: 181-186
• 19 Kemball-Cook G, Barrowcliffe TW. Factor VIII concentrates contain factor VIII procoagulant antigen bound to phospholipid. Br J Haematol 1986; 63: 425-434
• 20 Eyster ME, Goedert JJ, Samgadharan MG, Weiss SH, Gallo RC, Blattner WA. Development and early natural history of HTLV-III antibodies in persons with hemophilia. JAMA 1985; 253: 2219-2223
• 21 Ragni MV, Winkelstein A, Knigsley L, Spero JA, Lewis JH. 1986 update of HIV seroprevalence, seroconversion, AIDS incidence and immunologic correlates of HIV infections in patients with hemophilia A and B. Blood 1987; 70: 786-790
• 22 Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Haemostas Thromb 1972; 1: 75-95
• 23 Schleider MA, Nachmann RL, Jaffe EA, Coloman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509
• 24 Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 1980; 92: 159
• 25 Lechner K. Lupus anticoagulants and thrombosis. In: Thrombosis and Haemostasis. Verstraete M, Vermylen J, Lipnen R, Arnout J. (eds) Leuven University Press; Leuven: 1987. pp 525-547
• 26 Harris EN, Gharavi AE, Hedge U, Derue G, Morgan SH, Englert H, Chan JK H, Asheron RA, Hughes GR V. Anticardiolipin antibodies in autoimmune thrombopenic purpura. Br J Haematol 1985; 59: 231-234